论文部分内容阅读
7价肺炎球菌结合疫苗(PCV)已证明对儿童肺炎球菌菌血症有预防作用,亦能降低儿童肺炎总发病率,对降低儿童耳炎总发病的作用有限,但疫苗上市后监测显示其作用被低估。目前正在研制11价或更高价PCV。获准使用的成人23价肺炎球菌多糖疫苗(PPV)被证明对成人肺炎球菌菌血症有预防作用,但成人无肺炎球菌菌血症性肺炎的发病率仍较高,目前试图改进成人肺炎球菌疫苗,包括肺炎球菌结合疫苗和蛋白疫苗。
The 7-valent pneumococcal conjugate vaccine (PCV) has been shown to prevent pneumococcal bacteremia in children and reduce the overall incidence of pneumonia in children, with a limited impact on reducing the overall incidence of otitis in children, but surveillance after vaccination underestimated. Currently developing 11 or higher price PCV. The approved adult 23-valent pneumococcal polysaccharide vaccine (PPV) has been shown to have prophylaxis against pneumococcal bacteremia in adults, but the incidence of pneumococcal bacteremic pneumonia in adults is still high, and an attempt is now being made to improve the efficacy of an adult pneumococcal vaccine Including pneumococcal conjugate vaccines and protein vaccines.